Breaking Down Beijing Tiantan Biological Products Co., Ltd. Financial Health: Key Insights for Investors

Investors scrutinizing Beijing Tiantan Biological Products Co., Ltd. will find a mixed but data-rich profile: Q3 2025 revenue reached RMB 1.35 billion (up 9.96% YoY) while TTM revenue as of September 30, 2025, was RMB 6.42 billion (up 22.78% YoY), following 2024 full-year revenue of RMB 6.03 billion (up 16.44%); profitability shows a sharp Q3 swing with net profit attributable to shareholders of RMB 186.12 million (down 42.84% YoY) despite healthy margins - TTM net profit margin at 20.49% and operating profit margin at 30.15% - and returns of ROA 9.58% and ROE 14.38%; liquidity and valuation flags include operating cash flow of RMB 116.90 million for the first nine months of 2025 (a 91% decline YoY), a market capitalization of RMB 33.62 billion (Dec 10, 2025), P/S 5.23, P/B 3.37, TTM P/E 26.22 (forward P/E 23.66), EV/Revenue 6.41 and EV/EBITDA 14.57, while balance-sheet strength shows total assets of RMB 16.55 billion (up 4.29% from end-2024) and a low debt-to-equity of 1.55%; strategic and operational context includes 85 plasma collection stations across 15 provinces and the August 2025 decision to abandon a planned 21.03% acquisition of Pailin Biotech, leaving integration and competitive implications for the controlling shareholder to address - read on for a section-by-section breakdown of what these figures mean for risk, valuation, and growth prospects.

Beijing Tiantan Biological Products Co., Ltd. (600161.SS) - Revenue Analysis

Beijing Tiantan Biological Products Co., Ltd. reported continued top-line expansion through 2024-Q3 2025 with both quarterly and trailing measures showing double-digit annualized gains. Key figures and trends below provide a snapshot of sales momentum, efficiency per employee, and market valuation versus revenue.

• Q3 2025 revenue: RMB 1.35 billion (+9.96% YoY)
• TTM revenue as of 2025-09-30: RMB 6.42 billion (+22.78% vs. TTM 2024)
• Full-year 2024 revenue: RMB 6.03 billion (+16.44% vs. 2023)
• Revenue per employee: ~RMB 1.21 million (5,298 employees)
• Price-to-Sales (P/S) ratio: 5.23
• Market capitalization (2025-12-10): RMB 33.62 billion

• Implication: The TTM growth rate (22.78%) outpaces the single-quarter YoY gain (9.96%), indicating stronger earlier-quarter contributions within the 12-month window.
• Valuation context: At a P/S of 5.23 and market cap of RMB 33.62 billion, investors are pricing premium multiples on the company's sales base.
• Operational efficiency: Revenue per employee (~RMB 1.21M) provides a productivity benchmark versus peers in the biopharma sector.

Related corporate orientation: Mission Statement, Vision, & Core Values (2026) of Beijing Tiantan Biological Products Co., Ltd.

Beijing Tiantan Biological Products Co., Ltd. (600161.SS) - Profitability Metrics

• Q3 2025 net profit attributable to shareholders: RMB 186.12 million (down 42.84% YoY).
• Trailing twelve months (TTM) net profit margin: 20.49%.
• Operating profit margin: 30.15% (TTM basis).
• TTM return on assets (ROA): 9.58%.
• TTM return on equity (ROE): 14.38%.
• Basic and diluted EPS for Q3 2025: RMB 0.09 (down 42.84% YoY).
• Operating cash flow for first nine months of 2025: RMB 116.90 million (down 91% YoY).

• High operating profit margin (30.15%) signals strong core operational efficiency despite a sharp YoY profit decline in Q3 2025.
• Net profit margin of 20.49% indicates solid conversion of revenue to profit across the trailing twelve months.
• ROA (9.58%) and ROE (14.38%) show reasonable asset and equity returns relative to peers in biopharma, but recent cash flow deterioration (operating cash flow down 91% YoY) is a notable liquidity and sustainability risk.
• EPS contraction mirrors the net profit decline, underscoring earnings pressure in the latest quarter.

Beijing Tiantan Biological Products Co., Ltd. (600161.SS) Debt vs. Equity Structure

Key capital structure metrics for Beijing Tiantan Biological Products Co., Ltd. (600161.SS) highlight a conservative leverage profile and a market that prices the company at a premium to book value.

• Total debt-to-equity ratio: 1.55% - very low leverage versus equity.
• Market capitalization (as of 10 Dec 2025): RMB 33.62 billion.
• Price-to-book (P/B) ratio: 3.37 - equity valued at ~3.4x book.
• Enterprise value-to-revenue (EV/Revenue): 6.41.
• Enterprise value-to-EBITDA (EV/EBITDA): 14.57.
• Total assets (end Q3 2025): RMB 16.55 billion - up 4.29% vs. end-2024.

• Implication: Low debt-to-equity (1.55%) reduces financial risk and interest burden, leaving room for capital deployment or M&A if management chooses.
• Market premium: P/B of 3.37 and EV multiples (6.41 / 14.57) reflect investor expectations for growth, margin durability, or intangible assets not fully captured on the balance sheet.
• Balance sheet trend: Asset growth of 4.29% through Q3 2025 suggests modest expansion or reinvestment supporting revenue/operations.

Further investor context and shareholder composition can be reviewed here: Exploring Beijing Tiantan Biological Products Co., Ltd. Investor Profile: Who's Buying and Why?

Beijing Tiantan Biological Products Co., Ltd. (600161.SS) - Liquidity and Solvency

• Operating cash flow (first nine months of 2025): RMB 116.90 million (down 91% YoY), signaling constrained cash generation from core operations in the recent period.
• Basic and diluted EPS (Q3 2025): RMB 0.09, down 42.84% YoY - reflecting lower quarterly earnings per share despite solid margins on a TTM basis.
• Total assets (end of Q3 2025): RMB 16.55 billion, up 4.29% vs. end-2024, showing asset growth that can support future revenue capacity or balance-sheet flexibility.

• Profitability vs. cash generation: Net profit margin (20.49%) and operating margin (30.15%) indicate efficient cost control and high operating leverage, but the steep decline in operating cash flow suggests earnings quality or timing differences in working capital, collections, or one-off items warrant close monitoring.
• Returns: ROA of 9.58% and ROE of 14.38% show that the company generates healthy returns on assets and shareholder equity, supporting investor appeal despite short-term cash flow pressure.
• Balance-sheet capacity: The 4.29% growth in total assets to RMB 16.55 billion provides room for investment or financing options, though liquidity management will be critical given the cash flow drop.

Beijing Tiantan Biological Products Co., Ltd. (600161.SS) - Valuation Analysis

• TTM P/E: 26.22 - market paying ~26x trailing earnings.
• Forward P/E: 23.66 - implied earnings multiple falls modestly based on analysts' forward estimates.
• P/S: 5.23 - revenue multiple suggests robust revenue valuation vs peers in biotech/vaccine segment.
• P/B: 3.37 - equity valued >3x book, reflecting intangible assets, brand, and IP premium.
• EV/Revenue: 6.41 - enterprise-level revenue valuation signaling premium pricing of top-line.
• EV/EBITDA: 14.57 - indicates mid-teens valuation versus operating cash-profit proxy.

• Comparative context: these multiples place Beijing Tiantan Biological Products above commodity pharma but align with specialized vaccine/biologics peers where recurring government procurement, IP and regulatory barriers justify premiums.
• Investor implications: valuation assumes sustained revenue growth and stable margins; risk if product mix, pricing, or procurement dynamics shift.
• Watch points: forward earnings revisions, margin trajectory, R&D spend and product approval timelines that could compress or expand these multiples.

Beijing Tiantan Biological Products Co., Ltd. (600161.SS) - Risk Factors

• Abandoned acquisition: In August 2025 the company abandoned its planned acquisition of 21.03% of Pailin Biotech, citing prolonged transaction timelines and potential integration risks.
• Controlling shareholder intervention: The acquisition was deferred to the controlling shareholder, China National Biotec Group, to manage horizontal competition and related regulatory/strategic complexities.
• Liquidity pressure: Operating cash flow for the first nine months of 2025 was RMB 116.90 million, a 91% decline year‑over‑year, signalling potential short-term liquidity constraints and increased reliance on financing or working capital management.

• Profitability vs. cash conversion mismatch: Despite healthy margins (net margin 20.49%, operating margin 30.15%) and respectable ROA/ROE, the sharp drop in operating cash flow suggests earnings quality or timing differences (receivables build, inventory, prepayments) that could amplify funding risk.
• Strategic and integration risk: The halted Pailin Biotech stake acquisition highlights execution risk on inorganic growth and potential regulatory/antitrust scrutiny tied to horizontal competition among related state-controlled players.
• Controlling‑shareholder dynamics: Reliance on China National Biotec Group to resolve the acquisition and competition issues may concentrate decision-making and affect minority shareholder outcomes, including deal terms and strategic alignment.
• Financing and capital allocation risk: If operating cash flow weakness persists, the company may need to draw on debt, asset sales, or equity, which could dilute returns or increase leverage.
• Market and regulatory exposure: As a vaccine/biologics producer, product approval cycles, pricing pressure, and public health demand fluctuations remain material risks to revenue and cash flow stability.

Beijing Tiantan Biological Products Co., Ltd. (600161.SS) - Growth Opportunities

• Plasma supply moat: operates 85 plasma collection stations across 15 provinces and autonomous regions, supplying stable raw material flows for immunoglobulins, albumin, coagulation factors, and other plasma-derived therapies.
• Revenue momentum: 2024 annual revenue reached RMB 6.03 billion, a 16.44% increase versus 2023, demonstrating sustained demand and execution on volume/price mix.
• Scale benefits: expansive collection footprint supports higher utilization rates at fractionation facilities and lower incremental procurement cost per liter of plasma.
• Product diversification: opportunity to increase share of higher-margin specialty plasma products (e.g., monoclonal-like plasma derivatives) and expand hospital/retail penetration for existing immunoglobulin offerings.
• Geographic expansion: potential to deepen coverage within existing 15 provinces and enter additional provincial markets through new stations or partnerships.
• R&D and pipeline: investment in downstream biologics and enhanced processing technologies to improve yields and create differentiated offerings.

• Valuation context: P/S 5.23 and EV/Revenue 6.41 imply the market expects sustained above-market growth and margin expansion; P/B 3.37 shows a premium to carrying equity value.
• Near-term levers: raising plasma collection utilization, optimizing product mix toward higher-margin biologics, and operationalizing any capacity expansions to translate revenue growth into improved EBITDA and free cash flow.
• Risks to monitor: plasma supply regulatory changes, competitive pricing pressures, and execution risk on new product introductions or facility expansions.